The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis

Title
The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Authors
Keywords
Evolocumab, Low density lipoprotein cholesterol, Proprotein convertase subtilisin/kexin type 9, Meta-analysis, Randomized controlled trials
Journal
European Journal of Internal Medicine
Volume 38, Issue -, Pages 52-60
Publisher
Elsevier BV
Online
2016-10-28
DOI
10.1016/j.ejim.2016.10.009

Ask authors/readers for more resources

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now